RS50574B - (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline - Google Patents

(4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline

Info

Publication number
RS50574B
RS50574B RSP-2008/0125A RSP20080125A RS50574B RS 50574 B RS50574 B RS 50574B RS P20080125 A RSP20080125 A RS P20080125A RS 50574 B RS50574 B RS 50574B
Authority
RS
Serbia
Prior art keywords
benzothiazol
morpholin
piperidine
methoxy
amide
Prior art date
Application number
RSP-2008/0125A
Other languages
English (en)
Inventor
Alexander Flohr
Jean-Luc Moreau
Sonia Maria Poli
Claus Riemer
Lucinda Steward
Original Assignee
F. Hoffmann-La Roche Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34967309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS50574(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag. filed Critical F. Hoffmann-La Roche Ag.
Publication of RS50574B publication Critical patent/RS50574B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Jedinjenje formule koje je (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-l-karboksilne kiseline i njegove farmaceutski prihvatljive kiselinske adicione soli. Prijava sadrži još 11 patentnih zahteva.
RSP-2008/0125A 2004-05-24 2005-05-17 (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline RS50574B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04102262 2004-05-24
PCT/EP2005/005329 WO2005116026A1 (en) 2004-05-24 2005-05-17 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide

Publications (1)

Publication Number Publication Date
RS50574B true RS50574B (sr) 2010-05-07

Family

ID=34967309

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2008/0125A RS50574B (sr) 2004-05-24 2005-05-17 (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline

Country Status (39)

Country Link
US (1) US7368446B2 (sr)
EP (1) EP1753760B1 (sr)
JP (1) JP4668265B2 (sr)
CN (1) CN1956983B (sr)
AR (1) AR048973A1 (sr)
AT (1) ATE382619T1 (sr)
AU (1) AU2005247567B2 (sr)
BR (1) BRPI0511543B1 (sr)
CA (1) CA2567703C (sr)
CR (1) CR8703A (sr)
CY (1) CY1108104T1 (sr)
DE (1) DE602005004142T2 (sr)
DK (1) DK1753760T3 (sr)
DO (1) DOP2005000091A (sr)
EA (1) EA011279B1 (sr)
EC (1) ECSP067018A (sr)
ES (1) ES2297710T3 (sr)
GT (1) GT200500124A (sr)
HK (1) HK1105199A1 (sr)
HN (1) HN2005000238A (sr)
HR (1) HRP20080027T3 (sr)
IL (1) IL179364A (sr)
MA (1) MA28601B1 (sr)
MX (1) MXPA06013417A (sr)
MY (1) MY140011A (sr)
NO (1) NO336939B1 (sr)
NZ (1) NZ550763A (sr)
PA (1) PA8633901A1 (sr)
PE (1) PE20060274A1 (sr)
PL (1) PL1753760T3 (sr)
PT (1) PT1753760E (sr)
RS (1) RS50574B (sr)
SI (1) SI1753760T1 (sr)
SV (1) SV2006002125A (sr)
TN (1) TNSN06371A1 (sr)
TW (1) TWI358297B (sr)
UA (1) UA87142C2 (sr)
WO (1) WO2005116026A1 (sr)
ZA (1) ZA200609136B (sr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (sv) * 2001-06-25 2003-11-11 Niconovum Ab Anordning för administrering av en substans till främre delen av en individs munhåla
ES2708552T3 (es) * 2002-12-20 2019-04-10 Niconovum Ab Método para la preparación de un material particulado que contiene nicotina con una celulosa cristalina (en particular MCC)
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
AU2008279169A1 (en) * 2007-07-23 2009-01-29 Biotie Therapies, Inc 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder
JP5053459B2 (ja) 2009-01-12 2012-10-17 アイカジェン， インコーポレイテッド スルホンアミド誘導体
US8168785B2 (en) 2009-06-17 2012-05-01 Biotie Therapies, Inc. Benzothiazole derivatives
WO2011101861A1 (en) 2010-01-29 2011-08-25 Msn Laboratories Limited Process for preparation of dpp-iv inhibitors
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
WO2012060844A1 (en) * 2010-11-05 2012-05-10 Biotie Therapies, Inc A2a antagonists as cognition and motor function enhancers
ES2627541T3 (es) * 2012-04-20 2017-07-28 Ucb Pharma, S.A. Métodos para tratar la enfermedad de Parkinson
CA2988918A1 (en) 2015-06-19 2016-12-22 Biotie Therapies, Inc. Controlled-release tozadenant formulations
WO2018059531A1 (zh) * 2016-09-30 2018-04-05 苏州晶云药物科技有限公司 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
CN110997662B (zh) * 2017-08-21 2023-10-31 默克专利股份公司 作为腺苷受体拮抗剂的苯并咪唑衍生物
JP7287951B2 (ja) * 2017-08-21 2023-06-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしてのキノキサリン誘導体
WO2019141096A1 (zh) * 2018-01-19 2019-07-25 四川科伦博泰生物医药股份有限公司 取代脲类化合物及其制备方法和用途
AU2019405950A1 (en) 2018-12-20 2021-07-15 Biotie Therapies, Inc. Methods for treating cancer using tozadenant
DE102019110904B4 (de) 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH505543A (de) 1968-11-01 1971-04-15 Ciba Geigy Ag Schädlingsbekämpfungsmittel
LU63457A1 (sr) 1970-07-06 1971-11-12
US4028374A (en) 1975-11-03 1977-06-07 Morton-Norwich Products, Inc. Antibacterial thiocyanatobenzothiazoles
DE2656468A1 (de) 1976-12-14 1978-06-15 Boehringer Mannheim Gmbh N-(benzthiazol-2-yl)-oxamidsaeure- derivate und verfahren zu ihrer herstellung
KR930005004B1 (ko) 1985-04-15 1993-06-11 쟈안센 파아마슈우티카 엔. 부이. 치환된 n-[(4-피페리디닐)알킬]이환 축합 옥사졸아민 및 티아졸아민의 제조방법
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
IL90337A0 (en) 1988-05-24 1989-12-15 Pfizer Aromatic and heterocyclic carboxamide derivatives as antineoplastic agents
WO1990015801A1 (en) 1989-06-22 1990-12-27 Pfizer Inc. Substituted sulfonamides and related compounds in the treatment of asthma, arthritis and related diseases
ES2062248T3 (es) 1989-11-10 1994-12-16 Agrolinz Agrarchemikalien Procedimiento para la obtencion de ureas puras, asimetricamente disubstituidas.
EP0604657B1 (en) 1992-05-21 2000-01-12 Otsuka Pharmaceutical Factory, Inc. Phosphonic diester derivative
FR2753970B1 (fr) 1996-10-01 1998-10-30 Synthelabo Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique
JPH11130761A (ja) 1997-10-24 1999-05-18 Otsuka Pharmaceut Co Ltd ベンゾチアゾール誘導体
IL135176A0 (en) 1997-11-10 2001-05-20 Bristol Myers Squibb Co Benzothiazole derivatives and pharmaceutical compositions containing the same
AU764184B2 (en) 1998-01-23 2003-08-14 Pharmacia & Upjohn Company Oxazolidinone combinatorial libraries, compositions and methods of preparation
CN1325397A (zh) 1998-09-30 2001-12-05 纽罗根公司 2－哌嗪烷基氨基苯并吡咯衍生物∶多巴胺受体亚型特异配体
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
IL133680A0 (en) 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
JP5053498B2 (ja) 2000-05-12 2012-10-17 コーニング インコーポレイテッド 保護被覆をもつ光ファイバプリフォームを製造する方法
ATE385794T1 (de) * 2000-06-21 2008-03-15 Hoffmann La Roche Benzothiazolderivate zur behandlung von alzheimer und parkinson
US6727247B2 (en) * 2001-12-10 2004-04-27 Hoffman-La Roche Inc. Substituted benzothiazole amide derivatives
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives

Also Published As

Publication number Publication date
EP1753760B1 (en) 2008-01-02
JP2008500295A (ja) 2008-01-10
MXPA06013417A (es) 2007-01-23
CN1956983B (zh) 2010-05-26
GT200500124A (es) 2005-12-26
PL1753760T3 (pl) 2008-06-30
DE602005004142D1 (de) 2008-02-14
TWI358297B (en) 2012-02-21
SV2006002125A (es) 2006-02-15
HK1105199A1 (en) 2008-02-06
PE20060274A1 (es) 2006-04-14
EA200602048A1 (ru) 2007-06-29
TW200612937A (en) 2006-05-01
NZ550763A (en) 2010-07-30
JP4668265B2 (ja) 2011-04-13
ZA200609136B (en) 2008-07-30
TNSN06371A1 (fr) 2008-02-22
CA2567703A1 (en) 2005-12-08
DE602005004142T2 (de) 2009-01-02
PT1753760E (pt) 2008-02-12
BRPI0511543B1 (pt) 2022-05-10
SI1753760T1 (sl) 2008-04-30
IL179364A (en) 2013-01-31
CR8703A (es) 2007-10-04
ATE382619T1 (de) 2008-01-15
CY1108104T1 (el) 2014-02-12
MY140011A (en) 2009-11-30
NO336939B1 (no) 2015-11-30
CN1956983A (zh) 2007-05-02
PA8633901A1 (es) 2006-05-16
CA2567703C (en) 2013-03-05
EA011279B1 (ru) 2009-02-27
DOP2005000091A (es) 2005-06-29
DK1753760T3 (da) 2008-04-14
ES2297710T3 (es) 2008-05-01
US7368446B2 (en) 2008-05-06
IL179364A0 (en) 2007-03-08
AR048973A1 (es) 2006-06-14
HRP20080027T3 (en) 2008-05-31
ECSP067018A (es) 2006-12-29
AU2005247567B2 (en) 2010-09-02
BRPI0511543A (pt) 2008-01-02
MA28601B1 (fr) 2007-05-02
UA87142C2 (en) 2009-06-25
NO20065732L (no) 2006-12-22
HN2005000238A (es) 2008-07-14
EP1753760A1 (en) 2007-02-21
AU2005247567A1 (en) 2005-12-08
WO2005116026A1 (en) 2005-12-08
US20050261289A1 (en) 2005-11-24

Similar Documents

Publication Publication Date Title
RS50574B (sr) (4-metoksi-7-morfolin-4-il-benzotiazol-2-il)-amid 4-hidroksi-4-metil-piperidin-1-karboksilne kiseline
DK1585739T3 (da) Substituerede arylcyclopropylacetamider som glucokinaseaktivatorer
ME01992B (me) Jedinjenje diarilhidantoina
RS51780B (sr) Indazoli supstituisani amidom kao inhibitori poli(adp-riboza)polimeraze (parp)
RS53142B (sr) Jedinjenja koja imaju antagonističku aktivnost na crth2
RS52632B (sr) S-triazolil alfa-merkaptoacetanilida kao inhibitori hiv reversne transkriptaze
RS52099B (sr) Supstituisani benzimidazoli kao inhibitori kinaze
AR056764A1 (es) Aminopirimidinas utiles como inhibidores de quinasa
DE60335359D1 (de) Phthalazinonderivate
EA200500238A1 (ru) Новый способ синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
RS52679B (sr) Renin inhibitori
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
HRP20080666T3 (en) Cgrp receptor antagonists
WO2005074643A3 (en) Benzamide compounds useful as rock inhibitors
RS52823B (sr) Nova jedinjenja korisna za lečenje degenerativnih i inflamatornih bolesti
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
EA200870336A1 (ru) Полициклические производные циннамида
RS50140B (sr) Postupak za dobijanje perkihinina i njegova upotreba
HRP20080226T3 (en) Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors
RS53420B (sr) Kombinacije makrocikličnog jedinjenja hinoksalina koje je inhibitor hcv ns3 proteaze sa drugim hcv sredstvima
RS51200B (sr) (imidazol-1-il-metil)-piridazin kao blokator nmda receptora
RS52978B (sr) Fuzionisan amino piridin kao hsp90 inhibitori
EA200702670A1 (ru) Препарат тиенопиридинового ингибитора агрегации тромбоцитов
HRP20090162T1 (en) Quinolinone-carboxamide compounds as 5-ht4 receptor agonists